If you've found yourself unexpectedly humming the tune "Magic" lately, you're not alone. Thanks to the catchy commercial for ...

GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and ...

Glucagon-like peptide-1 agonist drugs, such as semaglutide, could save countless lives at risk due to diabetes and obesity.

Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss.

In people with diabetes, the "oatzempic" online diet fad may lead to increased glucose, decreased muscle mass, and ...

Semaglutide, a GLP-1 analog, may influence lipid metabolism and adipose tissue regulation by interacting with adipocytes, ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

The data contains additional information on GLP-1 use, such as social determinants of health and patient demographics.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are medications that help treat type 2 diabetes by mimicking the action of a hormone naturally produced in the body. Several brands of GLP-1 ...

New research suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors do not reduce the risk of dementia for patients ...

or recombinant human low dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). Dr. Arun Swaminathan, Coya’s Chief Business Officer, stated, “There has been ...